{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-013803","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.341971+00:00","generated_at":"2026-05-19T22:49:00.103548+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months","bullets":["Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.","95% CI lower bound of 12.5 months and 99% CI lower bound of 10.8 months shown.","New partial response (>=30% tumor reduction) observed after >20 months on treatment.","Longest-surviving patient reached 24.3 months and completed 32 cycles of therapy.","Potential FDA decision for ateganosine as early as next year."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-013803","json":"https://secwatch.observer/filing/0001641172-25-013803.json","markdown":"https://secwatch.observer/filing/0001641172-25-013803.md","text":"https://secwatch.observer/filing/0001641172-25-013803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225013803/0001641172-25-013803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225013803/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:49:00.103548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}